The Lp-PLA2 inhibitor darapladib reduces Lp-PLA2 activity by >60%;5 however, two phase III trials in 28 854 patients with stable coronary heart disease (CHD) or acute coronary syndrome (ACS), with about 3 years of treatment, failed to establish a protective role of darapladib for prevention of further major vascular disease.6 Here, PLA2G7 is linked to acute coronary syndrome.